Dexclamol, a candidate for neuroleptanalgesia.
Dexclamol, a potent neuroleptic, was found to potentiate the anesthetic actions of halothane when given at relatively small dose to albino rats. This effect was further enhanced by the addition of phenoperidine, a potent analgesic, at doses that per se did not influence the effects of halothane. Droperidol was used as a standard. In potentiating the effects of halothane, dexclamol behaved both qualitatively and quantitatively in a manner similar to droperidol. Dexclamol, however, was approximately 37 times less potent than droperidol in antagonizing the vasopressor effects of epinephrine.
D000758:Anesthesia; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004329:Droperidol / Q000494:pharmacology; D004347:Drug Interactions; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D006221:Halothane; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D009458:Neuroleptanalgesia; D010638:Phenoperidine / Q000494:pharmacology; D051381:Rats; D013997:Time Factors
D007546:Isoquinolines; D010638:Phenoperidine; D004329:Droperidol; D006221:Halothane; D004837:Epinephrine